
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. has shown a positive outlook through the modest increase in revenue estimates for its Brensocatib product, with projections for 2033E POS-adjusted worldwide sales reaching approximately $8.5 billion, up from $7.3 billion. This revision reflects a growing confidence in the near- and long-term potential of both Brensocatib and other pipeline developments, including Treprostinil Palmitil Inhalation Powder for pulmonary hypertension. Additionally, the company has decreased the terminal decline rate in its discounted cash flow calculations, indicating sustained optimism regarding the long-term viability of its product offerings.
Bears say
Insmed Inc faces significant challenges regarding the timely enrollment and completion of clinical studies for its key products, ARIKAYCE, brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP), which could adversely impact the company's probability of success estimations and overall valuation. Furthermore, projections suggest that TPIP may not be able to enter the idiopathic pulmonary fibrosis (IPF) market before 2034, contingent upon the approval of Tyvaso in 2027, which raises concerns about the company's growth potential and market competition. These factors contribute to a negative outlook for Insmed's stock, as delays in clinical development and regulatory approvals could severely affect its financial performance and investor confidence.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares